Dr Reddy's Subsidiary Completes Acquisition of Haleon's Global NRT Brands

In a regulatory filing, Dr Reddy's confirmed it made an upfront payment of GBP 458 million to complete the transaction.

Dr Reddy's Laboratories has announced recently that its Switzerland-based subsidiary has completed the acquisition of Haleon plc’s global portfolio of Nicotine Replacement Therapy (NRT) brands outside the United States.

The acquisition was finalized through the purchase of shares in Northstar Switzerland SARL, a Haleon group company.

In a regulatory filing, Dr Reddy's confirmed it made an upfront payment of GBP 458 million to complete the transaction.

With this acquisition, Northstar Switzerland and its subsidiaries, North Star OpCo and North Star Sweden AB, are now wholly-owned subsidiaries of Dr. Reddy’s, effective September 30, 2024.

Global Presence in the NRT Market

The acquired portfolio includes Nicotinell, a global leader in the NRT category with a presence in over 30 countries across Europe, Asia (including Japan), and Latin America.

It also includes regional brands such as Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The portfolio covers various product formats, including lozenges, patches, gums, and pipeline products, in all applicable global markets outside the U.S.

Dr Reddy's described the acquisition as a significant step in expanding its consumer healthcare and OTC wellness offerings, which it has been steadily growing in recent years.

The acquisition complements the company’s existing consumer healthcare efforts, including a recent joint venture with Nestle India.

Dr Reddy's sees this acquisition as a key move in building its global OTC healthcare business and further strengthening its presence in the consumer healthcare space.

In another development, in May this year, Dr. Reddy's Laboratories launched Nerivio, a drug-free wearable device for migraine treatment, in Spain through its subsidiary Reddy Pharma Iberia.

Developed by Theranica, Nerivio uses remote electrical neuromodulation (NER) technology to relieve migraines and has received USFDA clearance and CE marking.

The launch is part of Dr Reddy's strategy, including exclusive agreements to market and distribute Nerivio across multiple European countries, with the UK launch planned for June. The device targets users aged 12 and older, providing 18 sessions controlled via a mobile app for acute and preventive migraine treatment.

Stay tuned for more such updates on Digital Health News.